Targeting Mantle Cell Lymphoma with Anti-SYK Nanoparticles
Keywords:Nanotechnology, Personalized medicine, lymphoma, leukemia, cancer, oncology, kinase
The pentapeptide mimic 1,4-bis(9-O-dihydroquinidinyl)phthalazine / hydroquinidine 1,4-phathalazinediyl diether ("compound 61") (C-61) is the first reported inhibitor targeting the P-site of SYK. Here we report a nanotechnology platform to target C-61 to mantle cell lymphoma (MCL) cells. Liposomal nanoparticles (NP) loaded with C-61 were prepared using the standard thin film evaporation method. The entrapment of C-61 was obtained using the pH gradient procedure with lactobionic acid (LBA) being used as a low pH buffer inside the NP. Formulation F6A was selected as a lead candidate for further biological testing. The average diameter, zeta potential and C-61 content of the F6A NP was 40 nm, 0.1 mV, and 12.6 mg/ml, respectively. F6A induces apoptosis in SYK+ but not SYK- leukemia/lymphoma cells. We also evaluated the cytotoxic activity of F6A in the context of an in vitro artificial bone marrow assay platform based on a 3D scaffold with inverted colloidal crystal geometry mimicking the structural topology of actual bone marrow matrix. The ability of C-61 to induce apoptosis in ALL-1 cells was not adversely affected by the scaffolds. F6A, but not the drug-free NP formulation F6B, caused apoptosis of MCL cell lines MAVER-1 and MINO within 24h. Further development of rationally designed SYK inhibitors and their nanoscale formulations may provide the foundation for therapeutic innovation against a broad spectrum of lymphoid malignancies, including MCL.
Witzig TE. Current treatment approaches for mantle-cell lymphoma. J Clin Oncol 2005; 23: 6409-14. http://dx.doi.org/10.1200/JCO.2005.55.017
Brody J, Advani R. Treatment of mantle cell lymphoma: Current approach and future directions. Crtic Rev Oncol/Hematol 2006; 58: 257-65.
Williams ME, Connors JM, Dreyling MH, et al. Review. Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop. Leukemia & lymphoma 2011; 52: 24-33. http://dx.doi.org/10.3109/10428194.2010.532893
Delmonte A, Ghielmini M, Sessa C. Beyond monoclonal antibodies: New therapeutic agents in non-Hodgkin’s lymphomas. Oncologist 2009; 14: 511-25. http://dx.doi.org/10.1634/theoncologist.2008-0214
Samad N, Younes A. Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma. Onco Targets Ther 2010; 3: 167-78.
Qi W, Cooke LS, Liu X, et al. Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma. Biochemical Pharmacology, DOI 10.1016/j.bcp.2011.01.017, 2011
Singh AT, Evens AM, Anderson RJ, et al. All trans retinoic acid nanodisks enhance retinoic acid receptor mediated apoptosis and cell cycle arrest in mantle cell lymphoma. Br J Hematol 2010; 150: 158-69.
Romaguera JE, Fayad LE, McLaughlin P, et al. Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximan, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma. Br J Hematol 2010; 151: 47-53. http://dx.doi.org/10.1111/j.1365-2141.2010.08315.x
O’Connor OA, Portlock C, Moskowitz C, et al. A multicentre phase II clinical experience with the novel aza-epotholone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma. Br J Hematol 2008; 143: 201-9. http://dx.doi.org/10.1111/j.1365-2141.2008.07271.x
O’Connor OA, Moskowitz C, Portlock C, et al. Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre phase 2 clinical trial. Br J Hematol 2009; 145: 34-39. http://dx.doi.org/10.1111/j.1365-2141.2008.07466.x
Yee KW, Zeng Z, Konopleva M, et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2006; 12: 5165-73. http://dx.doi.org/10.1158/1078-0432.CCR-06-0764
Morschhauser F, Depil S, Jourdan E, et al. Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma. Ann Oncol 2007; 18: 370-75. http://dx.doi.org/10.1093/annonc/mdl395
Witzig TE, Vose JM, Zinzani L, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma. Annals of Oncology, advance access published January 12, 2011.
Witzig TE, Reeder CB, LaPlant BR, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia 2011; 25: 341-47. http://dx.doi.org/10.1038/leu.2010.226
Friedberg JW, Vose JM, Kelly JL, et al. The combination of bendamustine, bortezomib and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood, prepublished online Jan 14, 2011, DOI 10.1182/blood-2010-11-314708
Wang M, Oki Y, Pro B, et al. Phase II study of Tttrium-90-Ibritumomab Tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009; 27: 5213-18. http://dx.doi.org/10.1200/JCO.2009.21.8545
Jacobsen E, Freedman A. An update on the role of high-dose therapy with autologous or allogeneic stem cell transplantation in mantle cell lymphoma. Curr Opin Oncol 2004; 16: 106-13. http://dx.doi.org/10.1097/00001622-200403000-00004
Damon LE, Johnson JL, Niedzwiecki D, et al. Immunochemotherapy and autologous ste—cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol 2009; 27: 6101-108. http://dx.doi.org/10.1200/JCO.2009.22.2554
Greiner TC, Dasgupta C, Ho VV, et al. Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma. Proc Natl Acad Sci USA 2006; 103: 2352-7. http://dx.doi.org/10.1073/pnas.0510441103
Psyrri A, Papageorgiu S, Liakata E, et al. Phosphatidylinositol 3’-Kinase catalytic subunit a gene amplification contributes to the pathogenesis of mantle cell lymphoma. Clin Cancer Res 2009; 15: 5724-32. http://dx.doi.org/10.1158/1078-0432.CCR-08-3215
Hartmann EM, Campo E, Wright G, et al. Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling. Blood 2010; 116: 953-61. http://dx.doi.org/10.1182/blood-2010-01-263806
Leschchenko VV, Kuo P-Y, Shaknovich R, et al. Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma. Blood 2010; 116: 1025-34. http://dx.doi.org/10.1182/blood-2009-12-257485
Uckun FM, Qazi S. Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas. Expert Rev Anticancer Ther 2010; 10(9): 1407-18. http://dx.doi.org/10.1586/era.10.112
Rinaldi A, Kwee I, Taborelli M, et al. Genomic and expression profiling identifies the B cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Br J Hematol 2006; 132: 303-16. http://dx.doi.org/10.1111/j.1365-2141.2005.05883.x
Leseux L, Hamdi SM, Al Saati T, et al. Syk-dependent mTOR activation in follicular lymphoma cells. Blood 2006; 108(13): 4156-62. http://dx.doi.org/10.1182/blood-2006-05-026203
Tauzin S, Ding H, Burdevet D, Borisch B, Hoessli DC. Membrane-associated signaling in human B-lymphoma lines. Exp Cell Res 2011; 317(2): 151-62. http://dx.doi.org/10.1016/j.yexcr.2010.09.011
Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010; 115(13): 2578-85. http://dx.doi.org/10.1182/blood-2009-08-236471
Uckun FM, Qazi S, Ma H, Tuel-Ahlgren L, Ozer Z. STAT3 is a substrate of SYK tyrosine kinase in B-lineage leukemia/lymphoma cells exposed to oxidative stress. Proc Natl Acad Sci USA 2010; 107(7): 2902-7. http://dx.doi.org/10.1073/pnas.0909086107
Uckun FM, Ek RO, Jan ST, Chen CL, Qazi S. Targeting SYK Kinase-Dependent Anti-Apoptotic Resistance Pathway in B-lineage Acute Lymphoblastic Leukemia (ALL) Cells with a Potent SYK Inhibitory Pentapeptide Mimic. Br J Haematol 2010; 149(4): 508-17. http://dx.doi.org/10.1111/j.1365-2141.2010.08106.x
Uckun FM, Goodman P, Ma H, Dibirdik I, Qazi S. CD22 Exon 12 Deletion as a Novel Pathogenic Mechanism of Human B-Precursor Leukemia. Proc Natl Acad Sci USA 2010; 107: 16852-57. http://dx.doi.org/10.1073/pnas.1007896107
Uckun FM, Qazi S, Ozer Z, et al. Inducing apoptosis in chemotherapy-resistant B-lineage acute lymphoblastic leukemia (ALL) cells by targeting GRP78/HSPA5, a master regulator of the anti-apoptotic unfolded protein response (UPR) signaling network. Br J Haematol 2011; in press (MS# BJH-2011-00084).
Nichols JE, Cortiella J, Lee J, et al. In vitro analog of human bone marrow from 3D scaffolds with biomimetic inverted colloidal crystal geometry. Biomaterials 2009; 30(6): 1071-9. http://dx.doi.org/10.1016/j.biomaterials.2008.10.041
Davis ME, Chen Z, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008; 7: 771-82. http://dx.doi.org/10.1038/nrd2614
Cho K, Wang X, Nie S, Chen ZG, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 2008;14(5): 1310-6. http://dx.doi.org/10.1158/1078-0432.CCR-07-1441
Cheng WW, Allen TM. The use of single chain Fv as targeting agents for immunoliposomes: an update on immunoliposomal drugs for cancer treatment. Expert Opin Drug Deliv 2010; 7: 461-478. http://dx.doi.org/10.1517/17425240903579963